Allurion Executes 1-for-15 Reverse Stock Split to Regain Exchange Listing — Allurion Technologies, Inc.

Event summary

Allurion Technologies will execute a 1-for-15 reverse stock split effective June 18, 2026, reducing outstanding shares from ~15M to ~1M.
The move aims to regain compliance with NYSE listing standards or relist on NYSE American.
Shares will trade under temporary symbol ALURD for 20 days before reverting to ALUR.
All equity incentives, convertible notes, and warrants will be proportionally adjusted.
The reverse split was approved within the range authorized by shareholders at the 2025 annual meeting.

The big picture

Allurion's reverse stock split is a strategic maneuver to address listing requirements, aiming to enhance visibility and liquidity. This move comes amid broader trends of medical technology companies optimizing capital structures to strengthen market positioning. The success of this strategy will depend on both regulatory approval and investor response to the restructured share count.

What we're watching

Listing Success: Whether Allurion can successfully relist on a major exchange and the timeline for achieving this.
Market Impact: How the reverse split affects shareholder liquidity and investor perception of the company.
Commercial Strategy: The pace at which Allurion advances its U.S. commercial strategy post-relisting.